Literature DB >> 28493228

[Multimodal therapy of fibromyalgia syndrome : Updated guidelines 2017 and overview of systematic review articles].

M Schiltenwolf1, U Eidmann2, V Köllner3,4, T Kühn5, M Offenbächer6, F Petzke7, M Sarholz8, M Weigl9, B Wolf10, W Häuser11,12.   

Abstract

BACKGROUND: The regular update of the guidelines on fibromyalgia syndrome, AWMF number 145/004, was scheduled for April 2017.
METHODS: The guidelines were developed by 13 scientific societies and 2 patient self-help organizations coordinated by the German Pain Society. Working groups (n = 8) with a total of 42 members were formed balanced with respect to gender, medical expertise, position in the medical or scientific hierarchy and potential conflicts of interest. A search of the literature for systematic reviews on randomized controlled trials of multimodal therapy from December 2010 to May 2016 was performed in the Cochrane library, MEDLINE, PsycINFO and Scopus databases. Levels of evidence were assigned according to the classification system of the Oxford Centre for Evidence-Based Medicine version 2009. The strength of recommendations was achieved by multiple step formalized procedures to reach a consensus. Efficacy, risks, patient preferences and applicability of available therapies were weighed up against each other. The guidelines were reviewed and approved by the board of directors of the societies engaged in the development of the guidelines. RESULTS AND
CONCLUSION: The use of multimodal therapy (combination of aerobic exercise with at least one psychological therapy) with a duration of at least 24 h is strongly recommended for patients with severe forms of fibromyalgia.

Entities:  

Keywords:  Fibromyalgia syndrome; Guidelines; Medicine, evidence-based; Multicomponent therapy; Review, systematic

Mesh:

Year:  2017        PMID: 28493228     DOI: 10.1007/s00482-017-0205-2

Source DB:  PubMed          Journal:  Schmerz        ISSN: 0932-433X            Impact factor:   1.107


  6 in total

1.  Efficacy of multicomponent treatment in fibromyalgia syndrome: a meta-analysis of randomized controlled clinical trials.

Authors:  Winfried Häuser; Kathrin Bernardy; Bernhard Arnold; Martin Offenbächer; Marcus Schiltenwolf
Journal:  Arthritis Rheum       Date:  2009-02-15

Review 2.  [General treatment principles, coordination of care and patient education in fibromyalgia syndrome : Updated guidelines 2017 and overview of systematic review articles].

Authors:  F Petzke; W Brückle; U Eidmann; P Heldmann; V Köllner; T Kühn; H Kühn-Becker; M Strunk-Richter; M Schiltenwolf; M Settan; M von Wachter; M Weigl; W Häuser
Journal:  Schmerz       Date:  2017-06       Impact factor: 1.107

3.  [Methodology report of the 2017 guidelines on fibromyalgia syndrome].

Authors:  W Häuser; M Nothacker
Journal:  Schmerz       Date:  2017-06       Impact factor: 1.107

Review 4.  [Definition, diagnostics and therapy of chronic widespread pain and the (so-called) fibromyalgia syndrome in children and adolescents : Updated guidelines 2017].

Authors:  N Draheim; F Ebinger; E Schnöbel-Müller; B Wolf; W Häuser
Journal:  Schmerz       Date:  2017-06       Impact factor: 1.107

Review 5.  [Multicomponent therapy of fibromyalgia syndrome. Systematic review, meta-analysis and guideline].

Authors:  B Arnold; W Häuser; M Arnold; M Bernateck; K Bernardy; W Brückle; E Friedel; H J Hesselschwerdt; W Jäckel; V Köllner; E Kühn; F Petzke; M Settan; M Weigl; E Winter; M Offenbächer
Journal:  Schmerz       Date:  2012-06       Impact factor: 1.107

Review 6.  Predictors of multidisciplinary treatment outcome in fibromyalgia:a systematic review.

Authors:  Aleid de Rooij; Leo D Roorda; René H J Otten; Marike van der Leeden; Joost Dekker; Martijn P M Steultjens
Journal:  Disabil Rehabil       Date:  2012-08-14       Impact factor: 3.033

  6 in total
  7 in total

Review 1.  [Physiotherapy, occupational therapy and physical therapy in fibromyalgia syndrome : Updated guidelines 2017 and overview of systematic review articles].

Authors:  A Winkelmann; H Bork; W Brückle; C Dexl; P Heldmann; P Henningsen; L Krumbein; V Pullwitt; M Schiltenwolf; W Häuser
Journal:  Schmerz       Date:  2017-06       Impact factor: 1.107

Review 2.  [Definition, diagnostics and therapy of chronic widespread pain and the (so-called) fibromyalgia syndrome in children and adolescents : Updated guidelines 2017].

Authors:  N Draheim; F Ebinger; E Schnöbel-Müller; B Wolf; W Häuser
Journal:  Schmerz       Date:  2017-06       Impact factor: 1.107

3.  [Self-hypnosis training for in-hospital chronic pain patients : A retrolective observational study].

Authors:  Peter C Keil; Nicole Lindenberg; Christoph L Lassen; Bernhard M Graf; Jens Meier; Christoph H Wiese
Journal:  Schmerz       Date:  2018-06       Impact factor: 1.107

4.  Pain is not the major determinant of quality of life in fibromyalgia: results from a retrospective "real world" data analysis of fibromyalgia patients.

Authors:  Martin Offenbaecher; Niko Kohls; Thomas Ewert; Claudia Sigl; Robin Hieblinger; Loren L Toussaint; Fuschia Sirois; Jameson Hirsch; Miguel A Vallejo; Sybille Kramer; Javier Rivera; Gerold Stucki; Jörg Schelling; Andreas Winkelmann
Journal:  Rheumatol Int       Date:  2021-03-05       Impact factor: 2.631

5.  The Importance of Daily Activity for Reducing Fibromyalgia Symptoms: A Retrospective "Real World" Data Comparison of two Multimodal Treatment Programs.

Authors:  Sybille Kramer; Lana Deuschle; Niko Kohls; Martin Offenbächer; Andreas Winkelmann
Journal:  Arch Rheumatol       Date:  2020-04-17       Impact factor: 1.472

6.  Effectiveness of multicomponent treatment in patients with fibromyalgia: protocol for a systematic review and meta-analysis.

Authors:  Felipe Araya-Quintanilla; Héctor Gutiérrez-Espinoza; Jorge Fuentes; Fernanda Prieto-Lafrentz; Leonardo Pavez; Carlos Cristi-Montero; Iván Cavero-Redondo; Celia Álvarez-Bueno
Journal:  Syst Rev       Date:  2022-04-15

7.  Effectiveness of a multicomponent treatment versus conventional treatment in patients with fibromyalgia: Study protocol.

Authors:  Felipe Araya-Quintanilla; Héctor Gutiérrez-Espinoza; María Jesús Muñoz-Yánez; Iván Cavero-Redondo; Celia Álvarez-Bueno; Vicente Martinez-Vizcaíno
Journal:  Medicine (Baltimore)       Date:  2020-01       Impact factor: 1.817

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.